Dynavax Technologies (NASDAQ:DVAX) Price Target Lowered to $15.00 at The Goldman Sachs Group

Dynavax Technologies (NASDAQ:DVAX) had its target price reduced by The Goldman Sachs Group from $20.00 to $15.00 in a research note released on Thursday morning, Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

DVAX has been the subject of several other reports. StockNews.com downgraded shares of Dynavax Technologies from a buy rating to a hold rating in a research note on Tuesday, May 28th. HC Wainwright reissued a buy rating and issued a $29.00 target price on shares of Dynavax Technologies in a research note on Wednesday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $23.67.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX traded up $0.40 during trading hours on Thursday, reaching $11.10. 2,211,185 shares of the stock traded hands, compared to its average volume of 2,151,702. The company’s 50-day simple moving average is $11.22 and its two-hundred day simple moving average is $11.86. The company has a market capitalization of $1.45 billion, a P/E ratio of 185.00 and a beta of 1.28. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $15.15. The company has a quick ratio of 14.10, a current ratio of 15.20 and a debt-to-equity ratio of 0.36.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a net margin of 3.91% and a return on equity of 1.52%. The firm had revenue of $73.80 million for the quarter, compared to the consensus estimate of $76.92 million. During the same period last year, the firm posted $0.03 earnings per share. Equities research analysts forecast that Dynavax Technologies will post 0.12 EPS for the current year.

Insiders Place Their Bets

In other news, Director Francis Cano sold 3,615 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $11.93, for a total transaction of $43,126.95. Following the completion of the transaction, the director now directly owns 36,905 shares of the company’s stock, valued at $440,276.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 2.98% of the company’s stock.

Hedge Funds Weigh In On Dynavax Technologies

Hedge funds have recently made changes to their positions in the business. Duality Advisers LP purchased a new position in shares of Dynavax Technologies during the first quarter valued at about $227,000. Natixis Advisors L.P. grew its holdings in shares of Dynavax Technologies by 10.5% during the 4th quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 1,804 shares during the period. Executive Wealth Management LLC bought a new position in shares of Dynavax Technologies in the 4th quarter worth approximately $280,000. Boston Partners purchased a new position in shares of Dynavax Technologies in the 1st quarter valued at approximately $292,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Dynavax Technologies by 67.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company’s stock valued at $311,000 after purchasing an additional 10,143 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.